Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06869785

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Puerto Rico Multiple Sclerosis Ctr, Caguas, Puerto Rico

Loading trial locations.

About this study

This is a Phase 3, open label, parallel-group, multicenter study in participants with relapsing multiple sclerosis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent must be obtained prior to participation in the study.
  • Male or female study participants aged 18 to 60 years (inclusive) at screening.
  • Diagnosis of multiple sclerosis (MS) according to the 2017 Revised McDonald criteria (Thompson et al 2018). Relapsing forms of MS: relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS).

Exclusion criteria

  • Participants suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the Investigator or emergence of any clinically significant condition/disease (e.g. active systemic bacterial, viral or fungal infections) during screening prior to Day 1 which might result in safety risk for participants.
  • Participants with history of confirmed progressive multifocal leukoencephalopathy (PML) or neurological symptoms consistent with PML.
  • Participants at risk of developing or having reactivation of hepatitis
  • Emergence of active chronic disease (or stable but treated with immune therapy) prior to Day 1 of the immune system other than MS (e.g. rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or with immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency).
  • Pregnant or nursing (lactating) women
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system (except for basal cell carcinoma, or squamous cell carcinomas of the skin that have been treated with no evidence of recurrence in the past 3 months).
  • Participants taking prohibited therapies, including B cell targeted therapies (e.g. such as ocrelizumab, rituximab, ofatumumab, ublituximab, and inebilizumab)

Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

Ofatumumab approved dose

Biological

Approved dosage

Ofatumumab new dose

Biological

New dosage

Primary outcomes

  1. Ofatumumab plasma pharmacokinetics - area under the curve

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Ofatumumab plasma pharmacokinetics - minimum observed plasma concentration

    Time frame: Up to 12 weeks

  2. Ofatumumab plasma pharmacokinetics - maximum observed plasma concentration

    Time frame: Up to 12 weeks

  3. Incidence of Adverse events (AE) and Serious adverse events (SAE)

    Time frame: Up to 52 weeks

  4. Proportion of participants with anti-drug antibodies

    Time frame: Up to 52 weeks

  5. Participant B cell counts

    Time frame: Up to 52 weeks

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

An Open-label, Randomized, Parallel Group, Non-inferiority Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab, Followed by Extended Treatment in Participants With Relapsing Multiple Sclerosis

Acronym: FILIOS

Important dates

Study start
2025
Primary completion
2026
Study completion
2030
First posted
Mar 11, 2025
Registry last updated
May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.